Company Filing History:
Years Active: 2004
Title: Ingvil Sæterdal: Innovator in Cancer Immunotherapy
Introduction
Ingvil Sæterdal is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of cancer immunotherapy through her innovative research and development of isolated peptides. Her work focuses on harnessing the immune system to target cancer cells effectively.
Latest Patents
Ingvil Sæterdal holds a patent for her groundbreaking invention related to peptides. The patent describes isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer. These isolated peptides are capable of eliciting T cell immunity against cells harboring genes with such mutations. Additionally, the patent outlines cancer vaccines and therapeutically effective compositions containing these peptides.
Career Highlights
Ingvil Sæterdal is associated with Gemvax AS, a company dedicated to advancing cancer treatment through innovative solutions. Her work at Gemvax AS has positioned her as a key player in the development of novel cancer therapies.
Collaborations
Ingvil has collaborated with notable colleagues in her field, including Gustav Gaudernack and Jon Amund Eriksen. These collaborations have further enhanced her research and contributed to the advancement of cancer immunotherapy.
Conclusion
Ingvil Sæterdal's contributions to cancer immunotherapy through her innovative peptide research highlight her role as a leading inventor in the field. Her work continues to pave the way for new therapeutic approaches to combat cancer effectively.